Abstract:Risperidone (Risperdal) is a novel antipsychotic drug, with beneficial effects on both positive and negative symptoms of schizophrenia, and with a low incidence of extrapyramidal side effects (EPS). These particular properties have been attributed to the predominant and very potent serotonin 5-HT2 receptor antagonism of the drug combined with less potent dopamine D2 antagonism. In order to provide data on the degree to which various central neurotransmitter receptors are occupied in vivo, we performed ex vivo receptor occupancy studies with risperidone in comparison with clozapine and haloperidol in rats and guinea pigs. Various types of receptors, to which the compounds were known to bind to in vitro, were investigated precisely using receptor autoradiography in sections of the same rat brain except for histamine H1 receptors that were measured in the guinea-pig cerebellum. Risperidone (2 h after s.c. treatment) occupied 5-HT2 receptors at very low doses (ED50 = 0.067 mg/kg). Nearly full occupancy (> 80%) was achieved before H1, D2, alpha 1 and alpha 2 receptors became occupied (ED50 = 0.45, 0.66, 0.75 and 3.7 mg/kg, respectively). Clozapine displayed occupancy of H1 and alpha 1 receptors at low doses (ED50 = 0.15 and 0.58 mg/kg, respectively) and of 5-HT2, 5-HT1C, D2, alpha 2, cholinergic muscarinic and 5-HT1A receptors at higher doses (ED50 = 1.3, 1.8, 9.0, 9.5, 11 and 15 mg/kg, respectively). Haloperidol occupied D2 and alpha 1 receptors at low doses (ED50 = 0.13 and 0.42 mg/kg, respectively) and 5-HT2 receptors at a higher dose (ED50 = 2.6 mg/kg). Occupancy of receptor types occurred with similar ED50-values in various brain areas, e.g. D2 receptors in striatum and mesolimbic areas. The ED50-values for the ex vivo measured occupancy of 5-HT2 and D2 receptors were in good agreement with ED50-values for functional effects putatively mediated by these central receptors. The dose-dependent occupancy of D2 receptors proceeded more gradually with risperidone (slope in the caudate-putamen: 0.85) than with clozapine (slope: 1.44) or haloperidol (slope: 1.51). It has previously been suggested that partial D2 receptor occupancy may suffice to control the positive symptoms of schizophrenia, whereas higher D2 receptor occupancy would induce extrapyramidal symptoms (EPS). The dose ratio for high (75%) vs. low (25%) D2 receptor occupancy in the caudate-putamen, was 37.3 for risperidone, 8.4 for clozapine, and 7.9 for haloperidol.(ABSTRACT TRUNCATED AT 400 WORDS)

Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone

Structures of the 5-HT2A receptor in complex with the antipsychotics risperidone and zotepine

Risperidone-induced changes in DNA methylation from peripheral blood in first-episode schizophrenia parallel neuroimaging and cognitive phenotype

Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist

Dopaminergic Pharmacology Revealed by Structures of Human Dopamine D3 Receptor-G I Complexes

Structure-based drug design for dopamine D3 receptor.

Occupancy of Central Neurotransmitter Receptors by Risperidone, Clozapine and Haloperidol, Measured Ex Vivo by Quantitative Autoradiography

Structural insights into the human D1 and D2 dopamine receptor signaling complexes

Ligand recognition and biased agonism of the D1 dopamine receptor

The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia

Recent Advances in representative small-molecule DRD2 inhibitors: Synthetic Routes and clinical applications

In Silico Repositioning of Dopamine Modulators with Possible Application to Schizophrenia: Pharmacophore Mapping, Molecular Docking and Molecular Dynamics Analysis

Structural genomics of the human dopamine receptor system

Structure-based design of a novel third-generation antipsychotic drug lead with potential antidepressant properties

Structures of the human dopamine D3 receptor-Gi complexes

Selectivity and Activation of Dopamine D3R from Molecular Dynamics

Structure-Based Design of Novel G-Protein-Coupled Receptor TAAR1 Agonists as Potential Antipsychotic Drug Candidates

Cryo-EM structure of the dopamine transporter with a novel atypical non-competitive inhibitor bound to the orthosteric site

Effects of the Dopamine D3 Receptor (DRD3) Gene Polymorphisms on Risperidone Response: a Pharmacogenetic Study.

Aromatic linker variations in novel dopamine D2 and D3 receptor ligands

The Relationship Between the Therapeutic Response to Risperidone and the Dopamine D(2) Receptor Polymorphism in Chinese Schizophrenia Patients